Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 13
Phase 21

Trial Status

Completed2
Recruiting1
Other2

Role Distribution

Other Roles5

Activity Timeline

Clinical Trials (5)

NCT06514794Phase 2Recruiting
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Lymphoblastic LymphomaT-cell Acute Lymphoblastic Leukemia
StudydirectorStart date: 2025-01-31
NCT05674526Phase 1Active Not Recruiting
A Phase 1b Study of WU-NK-101 in Combination With Cetuximab
Colorectal Cancer MetastaticSquamous Cell Carcinoma of Head and Neck
StudydirectorStart date: 2024-05-21
NCT05509855Enrolling By Invitation
A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
T-cell Acute Lymphoblastic LeukemiaT-cell Lymphoblastic Lymphoma
StudydirectorStart date: 2022-08-22
NCT04984356Phase 1Completed
A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
Lymphoblastic LymphomaT-cell Acute Lymphoblastic Leukemia
StudydirectorStart date: 2022-01-14

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Beata Holkova, MD

Massey Cancer Center

Related
3 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, Acute

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Brigitte C Widemann, M.D.

National Cancer Institute (NCI)

Related
19 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, Acute

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Jae Park, MD

Memorial Sloan Kettering Cancer Center

Related
17 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, Acute

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Jorge Cortes, MD

M.D. Anderson Cancer Center

Related
24 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Qifa Liu

Nanfang Hospital, Southern Medical University

Related
33 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Similarity Score10%

Farhad Ravandi-Kashani, MD

M.D. Anderson Cancer Center

Related
14 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Jorge E Cortes, MD

M.D. Anderson Cancer Center

Related
8 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Similarity Score10%

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

Related
24 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Richard W Childs, M.D.

National Heart, Lung, and Blood Institute (NHLBI)

Related
15 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, Acute
Similarity Score10%

Yves Beguin, MD, PhD

CHU-ULg

Related
7 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, Acute
Similarity Score10%

Publications (0)

No publications found for this investigator.

Clinical Trials (5)

Showing 5 of 5 trials

NCT06514794Phase 2StudyDirector

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Lymphoblastic LymphomaT-cell Acute Lymphoblastic Leukemia
Recruiting
NCT05674526Phase 1StudyDirector

A Phase 1b Study of WU-NK-101 in Combination With Cetuximab

Colorectal Cancer MetastaticSquamous Cell Carcinoma of Head and Neck
Active Not Recruiting
NCT05470140Phase 1StudyDirector

A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia
Completed
NCT05509855StudyDirector

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

T-cell Acute Lymphoblastic LeukemiaT-cell Lymphoblastic Lymphoma
Enrolling By Invitation
NCT04984356Phase 1StudyDirector

A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

Lymphoblastic LymphomaT-cell Acute Lymphoblastic Leukemia
Completed

All 5 trials loaded